1. Kronik Böbrek Yetmezlikli Hastalarda Sinakalset Kullanımının Hematolojik Parametreler Üzerine Etkisi.
- Author
-
Altuntaş, Atila, Aksu, Oğuzhan, Akın, Davut, and Sezer, Mehmet Tuğrul
- Subjects
- *
HEMATOLOGY , *CALCIUM-sensing receptors , *KIDNEY disease treatments , *ANEMIA , *HYPERPARATHYROIDISM , *DRUG resistance , *PREVENTION - Abstract
Introduction: The reasons of anemia seen in patients with chronic (CRF) Include eritropoeitln deficiency-resistance, iron deficiency and üremic toxins. Elevated PTH levels play a role in resistance to EPO's effect. Cinecalcet is successfully used in secondary hyperparatiroidism. The control of hyperparatiroidism can contribute to diminishing of resistance to EPO and to sooner acquiring of target hemoglobin levels. Because of this the effect of cinecalcet on hemoglobin levels has been researched Material and Methods: The dialysis patients given cinecalcet are the study group and the patients not given cinecalcet are the control group. The study included 24 patients. The acceptance criterias to the study are patients Kt/V hemodialysis >1.2 for peritone dialysis, ferritin levels> 200, transferrin saturation > %20 and PTH >300 pg/ml. The index of eritropoeitin resistance at the beginning and at the end of 3 months, hemoglobine, the EPO dosage IU/kg/week is recorded. The data Is compared with appropriate statistical methods. Results: The dialysis age, Kt/V, Ca, P, CaxP, Hb values were similar at the beginning and after 3 months in both groups. The rises of Hb in the groups are meaningful. The PTH levels of the cinecalcet given group, at the beginning and after 3 months, are meaningfully higher than the control group (p<0.00019. There was no meaningful difference in EPO and ERI indexes of the groups. Conclusion: In this study no prominent effect of cinecalcet on anemia is detected in the cinecalcet group. For this purpose prospective studies of larger series are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF